Drug for the treatment of osteonecrosis and for the...

Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Phosphorus containing other than solely as part of an...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C514S002600, C514S007600, C514S008100

Reexamination Certificate

active

10470924

ABSTRACT:
A bisphosphonate for the treatment of osteonecrosis and/or osteonecrosis dissecans. The drug may further be used to prevent the onset of osteonecrosis and/or osteonecrosis dissecans and any complications associated with both diseases.

REFERENCES:
patent: 5476865 (1995-12-01), Panetta et al.
patent: 5755809 (1998-05-01), Cohen et al.
patent: 5843678 (1998-12-01), Boyle
patent: 2004/0176327 (2004-09-01), Okuno et al.
patent: 97-416017/39 (1994-07-01), None
patent: WO 94/14455 (1994-07-01), None
patent: WO 95/28936 (1995-11-01), None
patent: WO 98/41246 (1998-09-01), None
patent: WO 99/21589 (1999-05-01), None
patent: WO 00/21542 (2000-04-01), None
patent: WO 01/13922 (2001-03-01), None
patent: WO 01/16180 (2001-03-01), None
patent: WO 02/098307 (2002-12-01), None
Dannemann et al. (2007, Bone 40 :828-834).
Fulfaro et al. (1998, Pain 78:157-169).
Bohndorf, 1998, Eur. Radiol. 8:103-112.
Podworny et al., 1999, J. Rheumatol. 26 :1972-1982.
Teronen et al., 1999, Ann. N.Y. Acad. Sci. 878:453-465.
Boissier et al., 2000, Cancer Research 60:2949-2954.
McCawley et al., 2000, Mol. Med. Today 6:149-156.
Gschaidmeier et al., 2000, Ann. Oncol. 11 (Suppl. 42000):10-11.
H. Fleisch, “The Use of Bisphosphonates in Osteoporosis” The British Journal of Clinical Practice, 48(6):323-326 (Nov./Dec. 1994).
LC Williams et al., “Update on Systemic Glucocorticosteriods in Dermatology” Dermatologic Clinics, 19(1):63-77 (Jan. 2001).
Manolagas, Stavros C., “Birth and Death of Bone Cells: Basic Regulatory Mechanisms and Implications for the Pathogenesis and Treatment of Osteoporosis,” (2000)Endocrine Reviews, 21(2):115-137.
Daluiski et al. Bone morphogenetic protein-3 is a negative regulator of bone density. Nature Genetics, vol. 27 pp. 84-88, 2001.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Drug for the treatment of osteonecrosis and for the... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Drug for the treatment of osteonecrosis and for the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Drug for the treatment of osteonecrosis and for the... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-3929389

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.